Nationwide trends over 10 years in epidemiology and management of pancreatic ductal adenocarcinoma: A real-world study from the French administrative database - 03/08/24
, Christel Castelli b, Amandine Coffy b, Brigitte Tretarre c, David Piquemal d, Jean-Baptiste Bachet aHighlights |
• | Nationwide analysis of PDAC real-world treatments and outcomes over 10 years. |
• | Nearly 30 000 patients included between 2009 and 2018. |
• | Confirmation of the rising incidence of PDAC mainly among patients > 60 years. |
• | Significant increase of neoadjuvant strategies and chemotherapy delivery. |
• | Improved outcomes in treated patients and modest survival gain overall. |
Abstract |
Background & aims |
Significant progress has been made in the management of pancreatic ductal adenocarcinoma (PDAC) in recent years. In this population-based study, we aimed to compare incidence, therapeutic strategies, and survival outcomes of PDAC patients in France over a decade.
Methods |
This study was performed using a nationwide French database. All patients receiving care for PDAC during years 2009, 2014 and 2018 were included. Treatment modalities and survival outcomes were analyzed.
Results |
A total of 8143/8771/10494 patients were considered in 2009/2014/2018, respectively. Incidence increased mainly among patients aged >60 years. In localized PDAC, the proportion of patients receiving best supportive care (BSC) only decreased at 43.6/36.4/32.4 % and 27.8/29.1/34.3 % received chemo(radio)therapy alone. The rate of upfront surgery remained stable while 3/8/18 % of operated patients received neoadjuvant therapy. Median overall survival (OS) was 7.0/7.9/8.5 months in the overall population. Among treated patients, 1-year OS was 61.4/67.7/68.8 % and 30.3/36.3/38.8 % for localized and metastatic PDAC, respectively.
Conclusions |
This study confirms the rising incidence of PDAC. Improved outcomes were seen in localized PDAC, with a wider use of chemotherapy and neoadjuvant strategies, and in treated metastatic patients. A modest survival gain was seen overall, hindered by the still high rate of patients receiving BSC only.
Le texte complet de cet article est disponible en PDF.Keywords : PDAC, Incidence, Therapeutic strategies, Population-based
Plan
Vol 48 - N° 8
Article 102426- octobre 2024 Retour au numéro
Article précédent
- Silymarin suppresses proliferation and PD-L1 expression in colorectal cancer cells and increases inflammatory CD8+ cells in tumor-bearing mice
- Maysoon Al-Haideri
- The construction of a prognostic model by apoptosis-related genes to predict survival, immune landscape, and medication in cholangiocarcinoma
- Peng Shen, Yinsheng Shi, Pengcheng Xu, Linbin Rao, Zhengfei Wang, Junjie Jiang, Meiling Weng
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?